Daiichi Sankyo and MHLW agree Omicron XBB.1.5-adapted COVID-19 vaccine supply deal
Japanese drugmaker Daiichi Sankyo (TYO: 4568) revealed it has reached an agreement with Japan’s Ministry of Health, Labor and Welfare (MHLW) to supply the omicron XBB.1.5- adapted monovalent mRNA vaccine (DS-5670) against the novel coronavirus infectious disease (COVID19).
DS-5670 will be used in the current special temporary vaccination program against COVID-19 in Japan that began in the Fall of 2023. This agreement was concluded to supply 1.4 million doses in FY2023 under the condition that regulatory approval for DS-5670 should be granted by MHLW.
The company submitted a supplemental New Drug Application (sNDA) for DS-5670 to the MHLW in September 2023. Daiichi Sankyo is now preparing its production facilities to supply DS-5670, the first Japan-made COVID-19 mRNA vaccine, within this year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze